[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Pogodzinski MS, Sabri AN, Lewis JE, Olsen KD: Retrospective study and review of polymorphous low-grade adenocarcinoma. Laryngoscope; 2006 Dec;116(12):2145-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifteen patients had their initial treatment at our institution, and four patients presented with a recurrent tumor.
  • One patient had regional nodal disease 20 years after the initial procedure, and another had lung metastasis.
  • No patients received chemotherapy.
  • CONCLUSIONS: Polymorphous low-grade adenocarcinoma is an increasingly recognized malignancy that originates predominantly in the minor salivary gland.
  • The delayed local recurrences and regional nodal metastases noted in our series show that prolonged follow-up is needed.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Salivary Glands, Minor


2. Zhou CX, Shi DY, Ma DQ, Zhang JG, Yu GY, Gao Y: Primary oncocytic carcinoma of the salivary glands: a clinicopathologic and immunohistochemical study of 12 cases. Oral Oncol; 2010 Oct;46(10):773-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary oncocytic carcinoma of the salivary glands: a clinicopathologic and immunohistochemical study of 12 cases.
  • Oncocytic carcinoma (OC) of salivary gland origin is an extremely rare proliferation of malignant oncocytes with adenocarcinomatous architectural phenotypes, including infiltrative qualities.
  • To help clarify the clinicopathologic and prognostic features of this tumor group, herein, we report 12 OC cases arising from the salivary glands, together with follow-up data and immunohistochemical observations.
  • Most occurred in the parotid gland (10/12) with one in the palate and one in the retromolar gland.
  • The tumors were unencapsulated and often invaded into the nearby gland, lymphatic tissues and nerves.
  • Regional or distant metastases were found in 6 and 4 cases, respectively.
  • In summary, OC of salivary gland origin is a high-grade tumor, often with local recurrence, regional or distant metastasis, diagnosis of which based on a combination of clinical and histopathological features.
  • Complete surgical excision is the treatment of choice while the role of radiotherapy or chemotherapy is controversial, and careful follow-up is necessary.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Oxyphil Cells / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20843731.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Solomonov A, Rosenblatt E, Ben-Izhak O, Goralnik L, Yigla M: High-dose-rate endobronchial brachytherapy in endobronchial metastatic malignant chondroid syringoma. Respiration; 2001;68(4):406-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 65-year-old man with malignant chondroid syringoma (MCS) was found to have pulmonary metastases in the form of multiple pulmonary nodules 4 years after wide excision and adjuvant radiotherapy of a primary abdominal wall tumor.
  • Atelectasis of the lingula due to obstructive endobronchial metastasis, resistant to combination chemotherapy, led us to perform high-dose rate (HDR) endobronchial brachytherapy for the first time in this rare tumor with a favorable response.
  • This case emphasizes the role of HDR brachytherapy as a palliative procedure in endobronchial tumors not responding to other treatment modalities, even those considered to be radioresistant.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Adenoma, Pleomorphic / radiotherapy. Brachytherapy. Bronchial Neoplasms / radiotherapy. Bronchial Neoplasms / secondary. Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Syringoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11464090.001).
  • [ISSN] 0025-7931
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


Advertisement
4. Shet T, Arora B, Laskar S, Basak R, Kane S, Kurkure P: Epstein-barr virus-associated lymphoepithelioma-like carcinoma of mandible. Pediatr Dev Pathol; 2009 Mar-Apr;12(2):152-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the first case of an lymphoepithelioma-like carcinoma (LEC) of the mandible with a view to discuss probable histogenesis from salivary gland inclusions in the mandible, effective therapy, the unusual pattern of nodal metastases, and association with the Epstein-Barr virus.
  • An 11-year-old boy presented with a lytic lesion in the left mandible and bilateral neck node enlargement.
  • The patient received ifosfamide, cisplatin, and etoposide chemotherapy followed by a hemimandibulectomy, which did not reveal any residual tumor.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Disease-Free Survival. Humans. Lymph Nodes / pathology. Lymph Nodes / virology. Male. Mandible / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457481.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Nouraei SA, Ferguson MS, Clarke PM, Sandison A, Sandhu GS, Michaels L, Rhys-Evans P: Metastasizing pleomorphic salivary adenoma. Arch Otolaryngol Head Neck Surg; 2006 Jul;132(7):788-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasizing pleomorphic salivary adenoma.
  • OBJECTIVE: To address questions about the etiology, behavior, optimal treatment, and prognosis of metastasizing pleomorphic adenoma (MPA), we undertook a review of the literature (1953-2005) and constructed a virtual series of all identified cases of MPA, metastatic lesions that are very occasionally identified in patients with a history of pleomorphic salivary adenoma and, on detailed pathological evaluation, found to exhibit all the histological hallmarks of the preceding benign lesions.
  • There was an overwhelming history of incomplete surgery for pleomorphic salivary adenoma.
  • Bone was the most common site for metastases (45%), followed by the head and neck (43%) and lung (36%).
  • Developing distant lesions within 10 years of the primary tumor and presence of metastases in multiple sites were independent predictors of survival on Cox regression analysis.
  • Metastasectomy conferred significant survival advantage over nonoperative treatment (log-rank analysis, P<.02).
  • Chemotherapy and radiotherapy were of limited value.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847191.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


6. Hendriks JM, Grootenboers MJ, Schramel FM, van Boven WJ, Stockman B, Seldenrijk CA, ten Broecke P, Knibbe CA, Slee P, De Bruijn E, Vlaeminck R, Heeren J, Vermorken JB, van Putte B, Romijn S, Van Marck E, Van Schil PE: Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial. Ann Thorac Surg; 2004 Dec;78(6):1919-26; discussion 1926-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial.
  • BACKGROUND: Current 5-year survival after complete resection of pulmonary metastases is 20% to 40%, and many patients develop intrathoracic recurrences.
  • Isolated lung perfusion is an experimental technique to deliver high-dose chemotherapy to the lung without systemic exposure.
  • A phase I trial of isolated lung perfusion with melphalan (MN) combined with pulmonary metastasectomy for resectable lung metastases was conducted to define the dose-limiting toxicity and maximum tolerated dose.
  • METHODS: From May 2001 to August 2003, 16 patients underwent isolated lung perfusion with MN, followed by surgical resection of lung metastases.
  • Serum samples were obtained during the procedure.
  • The primary tumor was colorectal in 7 patients, renal in 5, sarcoma in 3, and salivary gland in 1.
  • Grade 3 pulmonary toxicity developed at a dose of 60 mg of MN at 37 degrees C in 2 of 3 patients at this dose, terminating the trial.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Melphalan / administration & dosage
  • [MeSH-minor] Adult. Aged. Chemotherapy, Cancer, Regional Perfusion. Colorectal Neoplasms / pathology. Combined Modality Therapy. Female. Humans. Kidney Neoplasms / pathology. Male. Middle Aged. Pulmonary Surgical Procedures. Salivary Gland Neoplasms / pathology. Sarcoma / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15561001.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  •  go-up   go-down


7. Taxy JB: Squamous carcinoma in a major salivary gland: a review of the diagnostic considerations. Arch Pathol Lab Med; 2001 Jun;125(6):740-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous carcinoma in a major salivary gland: a review of the diagnostic considerations.
  • CONTEXT: Squamous carcinoma in a major salivary gland has several possible sources:.
  • DESIGN: Eleven cases of squamous carcinoma in a major salivary gland are presented and the literature reviewed.
  • Five cases represented metastases from cutaneous squamous carcinomas.
  • CONCLUSION: The occurrence of squamous carcinoma in a major salivary gland exhibits a histologic sameness that precludes accurate subclassification and assignation of origin.
  • Also irrespective of tumor origin, the clinical approach to diagnosis and treatment is similar.
  • Adjuvant therapy (eg, radical neck dissection, radiation, chemotherapy) is not uniformly applied.
  • Most patients present with a sizable (>3-cm) mass for which total excision is attempted.
  • The traditional subclassification of squamous carcinoma in a major salivary gland may not be clinically relevant.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Mucins / metabolism. Parotid Neoplasms / metabolism. Parotid Neoplasms / pathology. Parotid Neoplasms / secondary. Submandibular Gland Neoplasms / metabolism. Submandibular Gland Neoplasms / pathology. Submandibular Gland Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371224.001).
  • [ISSN] 0003-9985
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  • [Number-of-references] 18
  •  go-up   go-down


8. Issing PR, Hemmanouil I, Wilkens L, Karstens H, Lenarz T: [Long term results in adenoidcystic carcinoma]. Laryngorhinootologie; 2002 Feb;81(2):98-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The major salivary glands were affected in 26 cases.
  • The exact distribution of the ACC was: parotid gland (n = 18), submandibular gland (n = 8), oral cavity (n = 10), paranasal sinuses (n = 11), nasopharynx (n = 4) and larynx (n = 3).
  • No definitive differentiation was possible in 10 specimens.
  • Except one patient all 54 underwent surgical therapy.
  • Postoperative radiotherapy was additionally given in 25 cases which was combined with a chemotherapy in 6 patients.
  • Lymphnode metastases were observed in 13 patients after a latency of 3.3 years in average, but predominantly pulmonary metastases as distant spread developed in 18 patients after 5.8 years significantly later.
  • CONCLUSIONS: Due to the uncommon biological behaviour with a slow growth on the one hand side and an aggressive local invasion on the other hand side the ACC can be regarded as a challenging malignant disease for the clinician whose adequate therapy does not allow any standardized regime.
  • [MeSH-major] Carcinoma, Adenoid Cystic. Mouth Neoplasms. Otorhinolaryngologic Neoplasms. Paranasal Sinus Neoplasms. Salivary Gland Neoplasms
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / surgery. Laryngeal Neoplasms / therapy. Lymphatic Metastasis. Male. Middle Aged. Nasopharyngeal Neoplasms / diagnosis. Nasopharyngeal Neoplasms / surgery. Nasopharyngeal Neoplasms / therapy. Neoplasm Recurrence, Local. Parotid Neoplasms / diagnosis. Parotid Neoplasms / surgery. Parotid Neoplasms / therapy. Prognosis. Retrospective Studies. Submandibular Gland. Time Factors

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11914946.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Langer CJ, Duffy K, Horwitz EM, Litwin S, Rosvold E, Schol J, Keenan E, Nicolaou N, Friedman CD, Ridge JA: Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy. Cancer Invest; 2006 Mar;24(2):164-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
  • Metastases were permitted if disease was predominantly locoregional.
  • Previously radiated patients received 150 cGy bid x 5, wk 1; then 120 cGy bid x 5 Q 2 wk x 3 (later increased to 150 cGy BID for the entire treatment).
  • Treatment fields included recurrent tumor only with 2 cm margins.
  • Granulocyte colony stimulating factor (G-CSF) days 6-12 (off treatment week) was added if cumulative neutropenia precipitated treatment delays.
  • Eight had received prior chemotherapy, 27 prior RT.
  • At dose level three, regular treatment delays of >or=1 week due to slow neutrophil recovery occurred.
  • Addition of G-CSF (dose level 3b) reduced treatment delays from 100 percent to 28 percent and decreased the incidence of Grade >or=2 neutropenia and mucositis.
  • Six of 7 patients at this dose level completed all 4 cycles of treatment and all received full dose RT (60 Gy).
  • Median time to progression in this group was 6 months, with median and one-year survival of 9.5 mos and 41 percent, respectively.
  • CONCLUSION: Concurrent daily cisplatin/paclitaxel and split course hyperfractionated RT (60 Gy) is feasible in previously radiated patients.
  • G-CSF, administered between each cycle, reduces the incidence of treatment delays.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Squamous Cell / therapy. Dose Fractionation. Head and Neck Neoplasms / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Drug Administration Schedule. Ear Neoplasms / mortality. Ear Neoplasms / therapy. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Male. Maximum Tolerated Dose. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Radiation-Sensitizing Agents / therapeutic use. Recombinant Proteins. Salivary Gland Neoplasms / mortality. Salivary Gland Neoplasms / therapy. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16537186.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Perrot E, Davy N, Poubeau P, Arvin-Berod C: [Chemotherapy with paclitaxel for lung metastases of cystic adenoid carcinoma. A case report and review of the literature]. Rev Pneumol Clin; 2003 Dec;59(6):371-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy with paclitaxel for lung metastases of cystic adenoid carcinoma. A case report and review of the literature].
  • [Transliterated title] Chimiothérapie par paclitaxel dans les métastases pulmonaires des carcinomes adénoïdes kystiques. A propos d'un cas et revue de la littérature.
  • Cystic adenoid carcinoma, which generally develops in the salivary glands, is a rare primary lung tumor.
  • Locoregional treatment classically associates surgery and radiotherapy.
  • Approximately half of the patients develop metastases; appropriate treatment with chemotherapy remains to be defined.
  • We report the case of a woman who developed lung and pleural metastases of a right submaxillary cystic adenoid carcinoma.
  • Chemotherapy with paclitaxel provided partial tumor response after three cycles.
  • We present a review of the literature on chemotherapy for cystic adenoid carcinoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Paclitaxel / therapeutic use. Pleural Neoplasms / drug therapy. Pleural Neoplasms / secondary. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14745344.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


11. Liu H, Yu GY: [Antimetastatic effects of genistein on salivary adenoid cystic carcinoma in vivo]. Zhonghua Kou Qiang Yi Xue Za Zhi; 2004 Sep;39(5):373-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Antimetastatic effects of genistein on salivary adenoid cystic carcinoma in vivo].
  • OBJECTIVE: To study the antimetastatic effects of genistein on salivary adenoid cystic carcinoma (ACC-M) in vivo.
  • The lung metastasis rates and the number of metastases were detected.
  • Apoptosis index (AI), the expression of VEGF and MMP-9 of the lung metastases were also observed.
  • RESULTS: Compared to the control groups, the number of metastases was significantly reduced in genistein treated group (P < 0.05).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Adenoid Cystic / drug therapy. Genistein / administration & dosage. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Animals. Female. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Mice. Mice, Nude. Random Allocation

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. GENISTEIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15498340.001).
  • [ISSN] 1002-0098
  • [Journal-full-title] Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
  • [ISO-abbreviation] Zhonghua Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; DH2M523P0H / Genistein
  •  go-up   go-down


12. Till BG, Martins RG: Response to paclitaxel in adenoid cystic carcinoma of the salivary glands. Head Neck; 2008 Jun;30(6):810-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to paclitaxel in adenoid cystic carcinoma of the salivary glands.
  • BACKGROUND: Paclitaxel is not considered to be an active drug in adenoid cystic carcinoma (ACC) of the salivary glands.
  • (1) a 58-year-old man with recurrent ACC who developed pulmonary metastases, had progressive disease after a good response to first-line chemotherapy, and then achieved a partial response to weekly single- agent paclitaxel; and (2) a 46-year-old woman with extensive thoracic ACC metastases who achieved a significant response after 2 cycles of paclitaxel chemotherapy.
  • RESULTS: The first patient died of progressive disease approximately 4 months after completing paclitaxel therapy, and the second patient had disease control after 6 cycles of paclitaxel.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Lung Neoplasms / drug therapy. Paclitaxel / therapeutic use. Salivary Gland Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979110.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


13. Stennert E, Kisner D, Jungehuelsing M, Guntinas-Lichius O, Schröder U, Eckel HE, Klussmann JP: High incidence of lymph node metastasis in major salivary gland cancer. Arch Otolaryngol Head Neck Surg; 2003 Jul;129(7):720-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of lymph node metastasis in major salivary gland cancer.
  • OBJECTIVE: To analyze the incidence and risk factors for clinically apparent and occult lymph node metastases in patients with major salivary gland cancers.
  • DESIGN: Cohort of patients with a median follow-up of 46 months (range, 1-174 months).
  • Patients were treated with surgery alone (55%); surgery and radiation therapy (43%); or a combination of surgery, radiation, and chemotherapy (2%).
  • MAIN OUTCOME MEASURE: Incidence of apparent and occult lymph node metastases.
  • CONCLUSIONS: We found a high incidence of lymph node metastasis from major salivary gland cancers.
  • Neck dissections should be considered as an integral part of the surgical approach in patients with major salivary gland cancer, especially if no postoperative radiation therapy is planned.
  • [MeSH-major] Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12874071.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Rosenthal DI, Chambers MS, Weber RS, Eisbruch A: A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. Semin Oncol; 2004 Dec;31(6 Suppl 18):25-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
  • Intensity modulated radiation therapy (IMRT) allows for relative parotid salivary gland sparing for patients undergoing treatment for head and neck squamous cell cancer, but is less reliable for sparing the submandibular glands.
  • Cytoprotection with amifostine (Ethyol; Medimmune Inc, Gaithersburg, MD) has been shown to decrease rates of acute and late xerostomia in patients undergoing radiation therapy for head and neck squamous cell cancer.
  • The addition of amifostine to IMRT may augment parotid salivary sparing, and add submandibular/sublingual, and minor salivary gland sparing resulting in greater salivary flow rates and a more physiologic saliva.
  • Eligible patients include those slated to receive definitive IMRT for early oropharynx cancer or postoperative RT, both without chemotherapy, for more advanced cancers.
  • Postoperative patients with nodal metastases, T3 and T4 primaries, perineural invasion, and lymphovascular invasion will be eligible.
  • Clinical target volume (CTV) 1 will receive 60 to 66 Gy, CTV2 will receive 60 Gy, and CTV3 will receive 54 to 57 Gy.
  • The mean dose goal for the parotid gland is 25 Gy.
  • Whole mouth and individual major salivary gland stimulated and unstimulated saliva will be collected before and after therapy at 6 weeks, 6 and 12 months.
  • Xerostomia outcomes will be correlated with salivary dose volume histogram data.
  • The results of this study will give an indication of the objective and subjective benefit of combined IMRT physical parotid salivary sparing and amifostine chemical cytoprotection for combined salivary gland sparing and reduction in the rate of xerostomia in patients undergoing IMRT for head and neck squamous cell cancer.
  • [MeSH-major] Amifostine / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Parotid Gland / radiation effects. Radiation-Protective Agents / therapeutic use. Submandibular Gland / radiation effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726519.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Protective Agents; M487QF2F4V / Amifostine
  •  go-up   go-down


15. Razfar A, Heron DE, Branstetter BF 4th, Seethala RR, Ferris RL: Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. Laryngoscope; 2010 Apr;120(4):734-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography-computed tomography adds to the management of salivary gland malignancies.
  • OBJECTIVES/HYPOTHESIS: To evaluate the efficacy of combined positron emission tomography-computed tomography (PET-CT) in identifying salivary gland malignancies and to examine the role of PET-CT in the management of these patients.
  • METHODS: Fifty-five patients with diagnosed salivary gland cancer who had undergone PET-CT scanning were retrospectively reviewed from January 2000 to October 2008.
  • The impact of PET-CT findings on therapeutic management was analyzed.
  • PET-CT also identified unrecognized distant metastases in the following sites: six lung, five bone, two distant lymph nodes, and one liver.
  • Three patients with recurrence underwent PET-CT scan-directed radiation and/or chemotherapy, whereas nine patients diagnosed with distant disease received palliative treatment.
  • CONCLUSIONS: PET-CT is useful for planning the most appropriate treatment by identifying clinically unrecognized disease.
  • PET-CT shows a high diagnostic accuracy for detecting disease recurrence and distant metastases, thus helping to determine whether patients are candidates for potentially curative or palliative treatment.
  • [MeSH-major] Positron-Emission Tomography / methods. Salivary Gland Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis / radionuclide imaging. Neoplasm Staging. Prognosis. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213798.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Krasić D, Radović P, Burić N, Cosić A, Katić V: [MALT lymphoma of the parotid salivary gland]. Vojnosanit Pregl; 2007 Jan;64(1):53-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MALT lymphoma of the parotid salivary gland].
  • BACKGROUND: Mucosa-associated lymphoid tissue (MALT) lymphoma was described for the first time in 1983 by Isaacson and Wright.
  • After the subtotal parotidectomy, using conservation of nerve facialis, the tissue blocks were fixed in 10% formaldehyde.
  • After the surgical therapy accompanied by chemotherapy, the patients were controlled at regular intervals, and residual MALT lymphoma did not appear.
  • CONCLUSION: MALT lymphoma is a rare tumor of the salivary glands, with the most frequent localization in the parotide gland.
  • It had a slow clinical course, without metastases in both patients.
  • The surgical therapy was accompained by adjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304725.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


17. Scott JX, Krishnan S, Bourne AJ, Williams MP, Agzarian M, Revesz T: Treatment of metastatic sialoblastoma with chemotherapy and surgery. Pediatr Blood Cancer; 2008 Jan;50(1):134-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic sialoblastoma with chemotherapy and surgery.
  • Tumors of the salivary gland are very uncommon in children.
  • Distant metastases are rare.
  • We present a case of sialoblastoma with lung metastases that developed in a 4-year-old girl adjacent to a congenital nevus in the left cheek.
  • The tumor was inoperable at diagnosis but the largest of the pulmonary metastases was removed surgically.
  • The patient responded well to chemotherapy and underwent surgical excision of the primary tumor, followed by three more courses of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / secondary. Parotid Neoplasms / pathology. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 16514617.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Den Hengst WA, Van Putte BP, Hendriks JM, Stockman B, van Boven WJ, Weyler J, Schramel FM, Van Schil PE: Long-term survival of a phase I clinical trial of isolated lung perfusion with melphalan for resectable lung metastases. Eur J Cardiothorac Surg; 2010 Nov;38(5):621-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of a phase I clinical trial of isolated lung perfusion with melphalan for resectable lung metastases.
  • OBJECTIVE: Surgical resection of lung metastases is a widely accepted procedure but 5-year survival rates remain low and vary between 20% and 50%.
  • Isolated lung perfusion (ILuP) is an experimental technique to deliver a high dose of chemotherapy to the lung, without systemic toxicity.
  • The primary tumour was colorectal in 10 patients, renal in eight, sarcoma in four and salivary gland in one.
  • Sixteen patients developed recurrent disease, of whom 11 died.
  • Overall- and disease-free 5-year survival rates were 54.8 ± 10.6% and 27.5 ± 9.5%, respectively with an overall median survival time (MST) of 84 months (95% confidence interval (CI): 41-128) and disease-free MST of 19 months (95% CI: 4-34).
  • Radiographic follow-up with chest computed tomography showed no long-term toxicity from ILuP.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Cancer, Regional Perfusion / methods. Lung Neoplasms / drug therapy. Melphalan / therapeutic use
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Epidemiologic Methods. Female. Forced Expiratory Volume. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Reoperation. Total Lung Capacity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20478715.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  •  go-up   go-down


19. Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L: Major and minor salivary gland tumors. Crit Rev Oncol Hematol; 2010 May;74(2):134-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Major and minor salivary gland tumors.
  • Malignant salivary gland tumors are rare.
  • Painless swelling of a salivary gland should always be considered as suspicious, especially if no sign of inflammation is present.
  • Signs and symptoms related to major salivary gland tumors differ from those concerning minor salivary gland tumors, as they depend on the different location of the salivary gland.
  • Surgical excision represents the standard option in the treatment of resectable tumors of both major and minor salivary glands.
  • Neutron, heavy ions or proton radiotherapy may be a treatment option for inoperable locoregional disease.
  • Surgery, irradiation or re-irradiation are treatment options for local relapse, whereas radical neck dissection is indicated for regional relapses.
  • Metastatic disease may be either treated with radiotherapy or palliative chemotherapy, depending on the site of metastases.
  • For highly selected patients the employment of anti-androgen therapy is indicated.
  • [MeSH-major] Carcinoma. Salivary Gland Neoplasms
  • [MeSH-minor] Animals. Digestive System Surgical Procedures / adverse effects. Digestive System Surgical Procedures / methods. Humans. Neoplasm Metastasis. Neoplasm Staging / methods. Prognosis. Recurrence. Salivary Glands, Minor / pathology. Salivary Glands, Minor / surgery

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19939701.001).
  • [ISSN] 1879-0461
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 149
  •  go-up   go-down


20. Magrini E, Pragliola A, Farnedi A, Betts CM, Cocchi R, Foschini MP: Cytogenetic analysis of myoepithelial cell carcinoma of salivary gland. Virchows Arch; 2004 Jan;444(1):82-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic analysis of myoepithelial cell carcinoma of salivary gland.
  • Myoepithelial cell carcinoma (MCC) of the salivary gland is a rare entity.
  • The patient was a 53-year-old man, with a rapidly growing lesion of the palate.
  • Despite complete surgical excision, radio- and chemotherapy, the lesion rapidly harboured local and distant metastases leading to the death of the patient, 4 months after the diagnosis.
  • On histological and ultrastructural examination, the primary tumour and the related metastases were composed of oval and spindle cells, with features of myoepithelial cell differentiation reported in the literature.
  • Our cytogenetic data differ from those described in benign or slowly growing salivary gland tumours showing myoepithelial cell differentiation.
  • [MeSH-major] Chromosomes, Human, Pair 17. Cytogenetic Analysis. Monosomy. Myoepithelioma / genetics. Salivary Gland Neoplasms / genetics

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 1986 Dec;23(4):305-13 [3022913.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 15;128(2):130-6 [11463451.001]
  • [Cites] Virchows Arch. 1997 Apr;430(4):339-42 [9134046.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):428-36 [12447671.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Aug;113(1):49-53 [10459346.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Feb;109(1):66-9 [9973962.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2314-9 [9191518.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Feb;30(2):161-7 [11135432.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):831-6 [10879734.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):761-74 [10843278.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • (PMID = 14994730.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / DNA-Binding Proteins; 0 / Microfilament Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / calponin; 68238-35-7 / Keratins
  •  go-up   go-down


21. Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL: Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol; 2005 Jan 20;23(3):585-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
  • PURPOSE: This study aimed to assess the antitumor activity of imatinib in adenoid cystic carcinoma (ACC) of the salivary gland expressing c-kit.
  • Fourteen patients had lung metastases, 14 had prior radiotherapy, and six had prior chemotherapy.
  • Overexpression of wild-type c-kit was not sufficient for clinical benefit from imatinib in ACC.
  • Accrual to this study was rapid for a relatively rare cancer, encouraging additional efforts to identify more effective systemic therapy for these patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / drug therapy. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / biosynthesis. Pyrimidines / therapeutic use. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Benzamides. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Sep 1;23(25):6271-3; author reply 6273-4 [16135502.001]
  • (PMID = 15659505.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01 CM 17102-01; United States / NCI NIH HHS / CM / N01 CM 17107-01
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


22. Yu Y, Guo W, Qiu WL, Zhou XJ: [Experimental study of hydroxycamptothecine and theprubicine in the treatment of adenoid cystic carcinoma lung metastases]. Zhonghua Kou Qiang Yi Xue Za Zhi; 2006 May;41(5):291-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experimental study of hydroxycamptothecine and theprubicine in the treatment of adenoid cystic carcinoma lung metastases].
  • OBJECTIVE: To investigate anticancer effect of hydroxycamptothecine and theprubicine in the treatment of established human adenoid cystic carcinoma (ACC) lung metastasis of nude mice and to determine the best therapy sequence of the two drugs.
  • Different treatment sequence was performed on these groups.
  • The area of metastases and lung tissue were analyzed by the images analysis system.
  • RESULTS: The size of the metastatic lesion in the treatment groups were smaller than that in the control group (P < 0.01).
  • The treatment effects between the group with simultaneous administration of HCPT and THP and the group with single drug administration were not different (P > 0.05).
  • No.5 and No.6 groups showed better effect of treatment than the other treatment groups (P < 0.05).
  • Because using two drugs together will decrease the anticancer effect, HCPT and THP should not be used simultaneously.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy
  • [MeSH-minor] Animals. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carcinoma, Adenoid Cystic / secretion. Epirubicin / administration & dosage. Female. Humans. Male. Mice. Mice, Nude. Salivary Gland Neoplasms / pathology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784612.001).
  • [ISSN] 1002-0098
  • [Journal-full-title] Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
  • [ISO-abbreviation] Zhonghua Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 67656-30-8 / 10-hydroxycamptothecin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


23. Bradley PJ: Adenoid cystic carcinoma of the head and neck: a review. Curr Opin Otolaryngol Head Neck Surg; 2004 Apr;12(2):127-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: Adenoid cystic carcinoma is an uncommon salivary gland malignancy that presents insidiously and is generally advanced when diagnosed.
  • Current effective treatment modalities include surgery and irradiation, but locoregional recurrences are frequent and may present as early as 2 years.
  • Patients survive with recurrent and metastatic disease for several years despite not being offered any treatment.
  • Molecular analysis of the tumors is being undertaken, with optimistic results capable of selecting high-risk patients who may benefit from adjuvant treatment such as chemotherapy SUMMARY: Little progress has been made in advancing "curative" treatment of adenoid cystic carcinoma of the head and neck.
  • The time is now opportune for a multicenter, randomized, controlled trial to identify patients who would benefit from adjuvant radiotherapy and/or chemotherapy in the control of locoregional recurrences and the prevention of distant metastases.
  • [MeSH-major] Carcinoma, Adenoid Cystic / therapy. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Biopsy, Needle. Chemotherapy, Adjuvant. Humans. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / pathology. Radiotherapy, Adjuvant. Skull Base Neoplasms / therapy

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15167050.001).
  • [ISSN] 1068-9508
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


24. Hsu YC, Lu HF, Huang CC, Hsu RF, Su CY: Malignant lymphoepithelial lesions of the salivary gland. Otolaryngol Head Neck Surg; 2006 Apr;134(4):661-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoepithelial lesions of the salivary gland.
  • OBJECTIVES: To describe a relatively large series of patients with uncommon malignant lymphoepithelial lesions (MLEL) in the salivary glands, to present treatment-outcome data to support therapeutic decision-making, and to evaluate the incidence of co-occurrence of MLEL and Epstein-Barr virus (EBV).
  • All lesions were surgically removed, with or without neck dissection, and the patients treated with radiotherapy or radiotherapy and chemotherapy.
  • RESULTS: With aggressive treatment, outcomes were good, regardless of the presenting stage, except when distal metastases were present.
  • CONCLUSION AND SIGNIFICANCE: This and previous investigations support the use of aggressive surgical excision of the tumor and local metastases and radiotherapy or radiotherapy and chemotherapy, as optimal treatment for MLEL.
  • [MeSH-major] Lymphangiosarcoma / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Combined Modality Therapy. Female. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / metabolism. Humans. In Situ Hybridization. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Viral / genetics. RNA, Viral / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564393.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral
  •  go-up   go-down


25. Dodd RL, Slevin NJ: Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol; 2006 Sep;42(8):759-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies.
  • It has a tendency for a prolonged clinical course, with local recurrences and distant metastases sometimes occurring many years after presentation.
  • Standard treatment for salivary gland ACC is surgery and post-operative radiotherapy.
  • The aim of this review was to examine the reported efficacy of various chemotherapy regimens and molecular therapies on recurrent/metastatic salivary gland ACC.
  • One hundred and fourteen publications were reviewed on chemotherapy as well as possible molecular targets of therapy, including KIT, epidermal growth factor receptor (EGFR), human epidermal growth receptor-2 (HER-2), oestrogen and progesterone receptors, proliferating cell nuclear antigen (PCNA), Ki-67 and the p53, bcl-2 and SOX-4 genes.
  • Reported response rates to combination chemotherapy are low and response duration generally short lived.
  • The response to molecular therapies is low also.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Treatment Outcome


26. Sharon E, Kelly RJ, Szabo E: Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine. Head Neck Oncol; 2010;2:12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Carcinoma ex pleomorphic adenoma is a rare histologic subtype of salivary gland cancer with an overall poor prognosis.
  • Limited histopathologic analyses have shown that some such tumors exhibit significant HER2/neu immunoreactivity, suggesting a potential role for HER2-based therapy.
  • We report here a case of a 58-year old man with metastatic carcinoma ex pleomorphic adenoma who achieved a sustained long term response to combination therapy with trastuzumab and capecitabine.
  • CASE PRESENTATION: A 58 year old man presented with T1N2bM0 carcinoma ex pleomorphic adenoma and underwent surgery followed by adjuvant radiation therapy.
  • Multiple metastases to bone were documented one year later.
  • Continued treatment has resulted in maintenance of disease control for over 2 years.
  • CONCLUSION: This case illustrates the successful long term treatment of carcinoma ex pleomorphic adenoma with targeted therapy with trastuzumab in combination with chemotherapy.
  • In the absence of definitive clinical trials which are unlikely to be performed due to the rarity of this tumor, case reports such as this one suggest potential utility for trastuzumab in combination with chemotherapy in the treatment of HER2/neu-overexpressing carcinoma ex pleomorphic adenoma.
  • [MeSH-major] Adenoma, Pleomorphic / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Salivary Gland Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3246-50 [17577021.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3978-84 [17761983.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):309-19 [18544445.001]
  • [Cites] J Laryngol Otol. 2009 Feb;123(2):250-2 [18405406.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):923-7 [1353853.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • [Cites] Head Neck. 2001 Sep;23(9):705-12 [11505478.001]
  • [Cites] Oral Oncol. 2002 Oct;38(7):706-13 [12167424.001]
  • [Cites] Oral Oncol. 2003 Oct;39(7):724-7 [12907212.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • (PMID = 20504363.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2889991
  •  go-up   go-down


27. Kikuchi Y, Hirota M, Iwai T, Aoki S, Chikumaru H, Kawabe R, Matsui Y: Salivary duct carcinoma in the mandible: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar;103(3):e41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary duct carcinoma in the mandible: a case report.
  • Salivary duct carcinoma (SDC) is a distinctive and aggressive neoplasm.
  • The most frequent site of origin is the parotid gland, followed by the submandibular gland.
  • SDC originating in the minor salivary glands, particularly in the ectopic glands within the mandible, is extremely rare.
  • We describe a 62-year-old man with SDC in the mandible, who presented with a painless lump in the right submandibular region (later identified as lymph node metastasis) and ipsilateral mental nerve palsy.
  • Histologic examination after ablative surgery revealed SDC originating in the mandible and cervical nodal metastases spreading to levels I-III.
  • The patient remains alive 59 months after presentation as a result of postoperative full-dose irradiation and regular intensive chemotherapy using TXT, 5-FU, and CDDP.
  • However, the patient has local recurrence and distant metastases to the lung and brain.
  • In this report, we also discuss the specific diagnostic criteria and developmental theories of intraosseous salivary gland tumors.
  • [MeSH-major] Mandibular Neoplasms / pathology. Salivary Ducts / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17321438.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Zeng Q, Tang PZ, Xu ZG, Qi YF, Wu XX, Liu WS: [Malignant minor salivary gland tumors of the larynx]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Jan;44(1):40-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant minor salivary gland tumors of the larynx].
  • OBJECTIVE: To study the clinical features, treatment and prognosis of malignant minor salivary gland tumors of the larynx.
  • METHODS: Treatment and outcome were retrospectively analyzed in a consecutive series of 15 patients with malignant minor salivary gland tumors of the larynx treated in this hospital from 1959 to 2005.
  • Fourteen had surgery (7 with adjuvant radiotherapy) and one was treated with radiotherapy plus chemotherapy.
  • RESULTS: With a median follow-up of 8 years (ranging from 2 to 16 years), 7 patients are alive.
  • Four patients died of distant metastases in a range of 2 to 10 years.
  • The other 4 patients were lost to follow-up after treatment (ranging from 2 years to 16 years).
  • Seven patients developed recurrent disease, 1 of whom had local recurrence alone, 1 had regional recurrence alone, 2 had distant metastases alone, and 3 had local and distant metastases.
  • CONCLUSIONS: Minor salivary gland carcinomas of the larynx are rare and they are prone to the local recurrence and the distant metastasis in advanced stage.
  • Distant metastases remain the principal cause of treatment failure.
  • Surgery is the primary treatment modality used in most cases and the radiotherapy combining surgery has better local and regional control rate.
  • [MeSH-major] Laryngeal Neoplasms / therapy. Salivary Gland Neoplasms / therapy. Salivary Glands, Minor / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19484987.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


29. Huber PE, Debus J, Latz D, Zierhut D, Bischof M, Wannenmacher M, Engenhart-Cabillic R: Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? Radiother Oncol; 2001 May;59(2):161-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Between 1983 and 1995, 75 patients with inoperable, recurrent, or incompletely resected adenoid cystic carcinoma of the head and neck received radiotherapy that consisted of either fast 14.1 MV DT neutrons (median dose 16 neutron Gy), linac-based photon irradiation (median dose 64 photon Gy), or both (median dose 8 neutron Gy and 32 photon Gy).
  • Follow-up ranged from 1 to 160 months (median 51 months), and the surviving patients had a minimum follow-up of 3 years at the time of analysis.
  • The survival is dictated by the tumor diseases due to distant metastases occurring in 29 (39%) of the 75 patients.
  • Positive lymph nodes were the only significant factor (P = 0.001) associated with the development of distant metastases although negative lymph nodes did not predict absence of distant metastases, but predicted a delay of occurrence.
  • In multivariate analysis postoperative radiotherapy (P = 0.003) and small tumor size (P = 0.01) were associated with high local control, while primary therapy (P = 0.006) and negative lymph nodes (P = 0.01) were associated with longer survival.
  • CONCLUSION: Fast neutron radiotherapy provides higher local control rates than a mixed beam and photons in advanced, recurrent or not completely resected adenoid cystic carcinoma of the major and minor salivary glands.
  • The type of radiation does not impact survival, which is dominated by the high number of distant metastases.
  • [MeSH-major] Carcinoma, Adenoid Cystic / radiotherapy. Neutrons / therapeutic use. Photons / therapeutic use. Salivary Gland Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Radiotherapy / adverse effects. Retrospective Studies. Survival Analysis. Treatment Outcome


30. Capelli M, Bertino G, Morbini P, Villa C, Zorzi S, Benazzo M: Neuroendocrine carcinomas of the upper airways: a small case series with histopathological considerations. Tumori; 2007 Sep-Oct;93(5):499-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the clinical and histopathological features of 2 moderately differentiated neuroendocrine carcinomas of the larynx, one large cell poorly differentiated neuroendocrine carcinoma of the oropharynx, and one small cell carcinoma of the minor salivary glands of the tongue.
  • The patient with small cell carcinoma was free from disease 26 months after radical surgery, while the other patients showed liver, lung and bone metastases 18, 26 and 24 months after the diagnosis despite radical surgery or concomitant intra-arterial chemotherapy and radiotherapy.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Lung Neoplasms / pathology. Neuroendocrine Tumors / pathology. Oropharyngeal Neoplasms / pathology. Salivary Gland Neoplasms / pathology. Tongue Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoid Tumor / pathology. Carcinoid Tumor / therapy. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy. Combined Modality Therapy. Humans. Immunoenzyme Techniques. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038886.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Licitra L, Grandi C, Prott FJ, Schornagel JH, Bruzzi P, Molinari R: Major and minor salivary glands tumours. Crit Rev Oncol Hematol; 2003 Feb;45(2):215-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Major and minor salivary glands tumours.
  • Malignant salivary gland tumours are rare.
  • Painless swelling of a salivary gland should always be considered as suspicious, especially if no sign of inflammation is present.
  • Signs and symptoms related to major salivary gland tumours differ from those concerning minor salivary gland tumours, as they depend on the different location of the salivary gland.
  • Surgical excision represents the standard option in the treatment of resectable tumours of both major and minor salivary glands.
  • Neutron radiation may be a treatment option for inoperable locoregional disease.
  • Surgery, irradiation or re-irradiation are treatment options for local relapse, whereas radical neck dissection is indicated for regional relapses.
  • Metastastic disease may be either treated with radiotherapy or palliative chemotherapy, depending on the site of metastases.
  • [MeSH-major] Salivary Gland Neoplasms

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12604131.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 51
  •  go-up   go-down


32. Visa L, Caballero M, Grau JJ: [Response to metronomic chemotherapy in a metastatic adenoid cystic carcinoma of the parotid gland]. Acta Otorrinolaringol Esp; 2010 Nov-Dec;61(6):452-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Response to metronomic chemotherapy in a metastatic adenoid cystic carcinoma of the parotid gland].
  • [Transliterated title] Respuesta a quimioterapia metronómica en un carcinoma adenoide quístico metastásico de parótida.
  • Formerly, salivary gland cancer was considered to be chemoresistant.
  • Chemotherapy is indicated when distant metastases or inoperable locorregional disease are observed, although the chemotherapy schedule is not well defined.
  • Data on chemotherapy treatment for adenoid cystic carcinoma consist of phase II trials.
  • Most of these studies analyze therapies with a combination of agents at full dose, although there is no clear evidence that such treatment improves survival.
  • The administration of cytotoxic agents with low doses at frequent, regular intervals with no drug-free interruptions is known as metronomic chemotherapy.
  • Most head-to-head studies show similar or even superior therapeutic results with metronomic scheduling than with a maximum tolerated dose regime.
  • Our case report shows for first time the clinical activity of low-dose paclitaxel and cisplatin chemotherapy given separately as a single agent in metastatic adenoid cystic carcinoma of the parotid.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / secondary. Cisplatin / administration & dosage. Paclitaxel / administration & dosage. Parotid Neoplasms / drug therapy. Parotid Neoplasms / pathology
  • [MeSH-minor] Drug Administration Schedule. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 20152955.001).
  • [ISSN] 1988-3013
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Seok JY, Lee KG: Cytologic features of metastatic lymphoepithelial carcinoma in pleural fluid: a case report. Acta Cytol; 2009 Mar-Apr;53(2):215-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lymphoepithelial carcinoma of the salivary gland is a rare undifferentiated or poorly differentiated squamous cell carcinoma associated with abundant inmphocytes.
  • Only a handful of reports descibe the cytologic features of fine needle aspiration in lymphoepithelial carcinoma of the salivary gland and lymph nodes.
  • CASE: A 29-year-old man presented with a painless mass in his right parotid gland.
  • After the surgical specimen was evaluated, the mass was diagnosed as a lymphoepithelial carcinoma, which extended to the periglandular soft tissue with lymph node metastasis.
  • Despite radiation and chemotherapy, multiple mediastinal lymph node metastases, including in the right hilar lymph nodes, occurred.
  • Pulmonary atelectasis of the right upper lobe and a right pleural effusion developed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365979.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Dawson SJ, Murray RM, Rischin D: Hypocalcemia associated with bone metastases in a patient with salivary-gland carcinoma. Nat Clin Pract Oncol; 2006 Feb;3(2):104-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypocalcemia associated with bone metastases in a patient with salivary-gland carcinoma.
  • BACKGROUND: A 70-year-old man presented with a smooth lump on his buccal mucosa and right-sided cervical lymphadenopathy.
  • Staging investigations revealed extensive sclerotic bone metastases and the patient subsequently underwent palliative radiotherapy to the right face and cervical region.
  • Seven months later he presented with a 4-day history of fatigue, muscle cramps, ataxia, paraesthesia, and blurred vision.
  • DIAGNOSIS: Undifferentiated carcinoma of the salivary gland with sclerotic bone metastases and hypocalcemia.
  • MANAGEMENT: Palliative radiotherapy to the right face and cervical region, infusions of calcium gluconate and calcium chloride, oral calcium carbonate, vitamin D and magnesium, palliative chemotherapy (carboplatin and 5-fluorouracil), and whole brain radiotherapy.
  • [MeSH-major] Bone Neoplasms / therapy. Carcinoma / therapy. Hypocalcemia / etiology. Salivary Gland Neoplasms / therapy
  • [MeSH-minor] Aged. Humans. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462851.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


35. Preisegger KH, Beham A, Kopp S, Jessernigg G, Gugl A, Stammberger H: Prognostic impact of molecular analyses in adenoid cystic carcinomas of the salivary gland. Onkologie; 2001 Jun;24(3):273-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of molecular analyses in adenoid cystic carcinomas of the salivary gland.
  • BACKGROUND: Adenoid cystic carcinoma (ACC) of the salivary gland is a generally slow-growing but highly malignant neoplasm with a remarkable capacity for recurrence.
  • Prognosis is greatly influenced by the histological subtype (tubular, cribriform or solid), presence of tumour at the margins, anatomic size, and lymph node metastases.
  • These molecules were chosen because of their proven association with poor prognosis and therapy resistance in other malignancies.
  • Further, it could be demonstrated for the first time that proteins known for their association with radio- and chemotherapy resistance can be overexpressed in some ACCs suggesting that those molecules could influence the outcome of new therapeutical approaches.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] DNA Mutational Analysis. Gene Expression Regulation, Neoplastic / physiology. Humans. Immunoenzyme Techniques. Neoplasm Recurrence, Local / pathology. Polymerase Chain Reaction. Prognosis. Salivary Glands / pathology. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger GmbH, Freiburg
  • (PMID = 11455221.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng; ger
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down






Advertisement